7/14/2009

Abbott Laboratories and GlaxoSmithKline are teaming up to develop a molecular diagnostic test that screens for the MAGE-A3 antigen found in nonsmall-cell lung cancer tumors. The partnership comes as GSK works on the late-stage development of a drug that targets the MAGE-A3 protein.

Full Story:
Forbes

Related Summaries